Medibank Private Ltd (ASX:MPL) is an Australian private health insurer operating the Medibank and ahm brands, while also providing health services through its Medibank Health division. The FY26 result shows steady core insurance operations alongside faster growth in the smaller health-services arm, increasing the …
Mesoblast Limited (ASX:MSB) develops allogeneic cell medicines made from donor-derived mesenchymal cells. FY26 was its first full year of United States sales for Ryoncil, or remestemcel-L, approved for children with steroid-refractory acute graft-versus-host disease. The result established a material commercial revenue base while clinical …
For the year ended 30 June 2026, Cochlear reported sales revenue of about A$2.34 billion, representing 2% constant-currency growth. Underlying net profit was A$322.4 million. Operating cash flow reached A$368 million, while the full-year dividend was A$3.45 per share, including a final dividend of …
CSL Limited (ASX:CSL) is a global biotechnology company operating across plasma-derived therapies, influenza vaccines and specialty medicines through CSL Behring, CSL Seqirus and CSL Vifor. Its FY26 result showed a clear split between operating performance and large accounting write-downs, making the outlook for Behring, …
Pro Medicus develops medical imaging software used by hospitals, radiology groups and other healthcare providers. Its Visage platform enables clinicians to view, manage and analyse large medical imaging files across multiple sites. TheBusinessearns much of its revenue under long-term contracts linked to imaging volumes, …
Syntara Limited (ASX:SNT) has provided an update on two clinical programs targeting scarring conditions. The first is the SNT-9465 Phase 1b study in hypertrophic sternotomy scars, where recruitment of the initial cohort is nearing completion and the study has been expanded to 30 participants. …
WhiteHawk Limited (ASX:WHK) has reported that Quixxi's Clarity AI platform has secured a four-year binding contract with a major Italian industrial group, valued at A$635,237.96 and commencing on 1 November 2026. WhiteHawk agreed to acquire Quixxi on 13 April 2026, and the company has …
NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has appointed Southern Star Research as the contract research organisation, or CRO, for its planned Phase 2 clinical trial in refractory Crohn's disease. The trial is intended to run across Australia and the United States, and the company is targeting …
CSL is a global biotechnology company operating through CSL Behring, CSL Seqirus and CSL Vifor. Its businesses span plasma-derived therapies, influenza vaccines, iron deficiency treatments and other specialty medicines. Earnings are influenced by plasma collection volumes, product demand,Manufacturingefficiency, pricing, reimbursement and competition across major …
Pro Medicus Limited (ASX:PME) is a healthcare technology company providing medical imaging software solutions to hospitals and imaging groups. Its Visage platform enables the viewing and management of medical images through cloud-based technology. During FY2026, the company continued expanding its customer base while progressing …